Amorphous Bradykinin B2 Antagonist Solid Dispersions for Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of bradykinin B2 receptor antagonists with chemical structure Formula (1) face challenges due to poor solubility, leading to unreliable oral delivery, variable absorption rates, and low bioavailability, necessitating the development of stable and effective pharmaceutical compositions for both acute and chronic treatments.
Innovation Solution
The development of solid dispersions comprising amorphous bradykinin B2 receptor antagonists homogeneously dispersed in pharmaceutically acceptable polymers, such as HPMCAS or copovidone, which are prepared using methods like melt extrusion or spray drying, enabling both immediate and extended-release formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds of Formula (1) are used as BK B2 receptor antagonists, then pharmacological activity and tolerability are improved, but solubility in physiological media deteriorates
Solution Approach 1:
The patent changes the physical state parameter of the active ingredient from crystalline to amorphous form, which fundamentally alters solubility characteristics. The amorphous form eliminates crystal lattice energy requirements for dissolution, enabling compounds of Formula (1) to achieve adequate solubility in physiological media while maintaining their pharmacological activity as BK B2 receptor antagonists
Solution Approach 2:
The patent creates composite solid dispersion systems where the amorphous active ingredient is dispersed within a polymer matrix (such as hydroxypropyl methylcellulose acetate succinate or copovidone). This composite structure provides both the pharmacological activity of the BK B2 receptor antagonist and the solubility enhancement from the amorphous dispersed state, resolving the contradiction between maintaining drug activity and improving solubility
2Ease of manufacture
If conventional formulations are used, then manufacturing simplicity is maintained, but oral delivery reliability and bioavailability deteriorate
Solution Approach 1:
The patent employs established solid dispersion manufacturing techniques (hot-melt extrusion, spray drying, freeze drying) that utilize parameter changes during processing. These conventional manufacturing methods produce amorphous dispersions that reliably improve oral delivery and bioavailability of compounds of Formula (1) without requiring entirely new manufacturing approaches
Solution Approach 2:
The patent introduces polymer carriers (hydroxypropyl methylcellulose acetate succinate, copovidone, or HPMC) as intermediaries that facilitate the dissolution and absorption of the poorly soluble BK B2 receptor antagonist. These polymer intermediaries create a solubilizing environment that enhances oral delivery reliability while using standard pharmaceutical manufacturing processes
3Stability of the object's composition
If crystalline form is used, then physical stability is improved, but dissolution rate and absorption reliability deteriorate
Solution Approach 1:
The patent changes the physical state from crystalline to amorphous, which eliminates the high crystal lattice energy that must be overcome for dissolution. This parameter change dramatically increases the dissolution rate and absorption reliability of compounds of Formula (1) while the resulting solid dispersions maintain adequate physical stability through the polymer matrix
Solution Approach 2:
The patent performs preliminary action by pre-dispersing the active ingredient in amorphous form within the polymer matrix during manufacturing. This preliminary amorphization and dispersion prevents recrystallization during storage and ensures rapid dissolution upon administration, addressing both dissolution rate and absorption reliability before the product reaches the patient
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersions provide rapid and complete release of the active ingredient, reducing variability in release rates and improving bioavailability, with stable drug profiles and effective treatment of conditions responsive to bradykinin B2 receptor modulation, including angioedema and various inflammatory disorders.
Implementation Method 1
The solid dispersions are further characterised in that they comprise the BK B2 receptor antagonist in amorphous form, and homogeneously dispersed in a pharmaceutically acceptable polymer
Implementation Method 2
which are prepared using methods like melt extrusion or spray drying
Implementation Method 3
which are prepared using methods like melt extrusion or spray drying
Data Source
AI summary
The invention relates to solid dispersions for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: Formula (1) such as (S)-/V-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1/f-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(di-fluoromethoxy)acetamide. The solid dispersions comprise the BK B2 receptor antagonist in the amorphous form and homogeneously dispersed in a pharmaceutically acceptable polymer. Furthermore, methods for preparation and uses of the solid dispersions, including therapeutic uses, are provided.